Breaking News Instant updates and real-time market news.

PINS

Pinterest

$0.00

(0.00%)

, FIVE

Five Below

$134.74

-0.22 (-0.16%)

10:19
04/15/19
04/15
10:19
04/15/19
10:19

Fly Intel: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pinterest (PINS) initiated with a Neutral at DA Davidson. 2. Five Below (FIVE) initiated with a Buy at BofA/Merrill. 3. Levi Strauss (LEVI) initiated with an Outperform at Telsey Advisory, an Overweight at JPMorgan, a Buy at Citi and Guggenheim, an Equal Weight at Morgan Stanley, and a Neutral at Goldman Sachs and BofA/Merrill. 4. Tocagen (TOCA) initiated with a Market Perform at SVB Leerink. 5. Alcon (ALC) initiated with a Buy at Jefferies, while Allergan (AGN) was initiated with a Hold. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

PINS

Pinterest

$0.00

(0.00%)

FIVE

Five Below

$134.74

-0.22 (-0.16%)

LEVI

Levi Strauss

$22.79

0.33 (1.47%)

TOCA

Tocagen

$9.91

-0.35 (-3.41%)

ALC

Alcon

$54.99

0.5 (0.92%)

AGN

Allergan

$143.52

-1.42 (-0.98%)

  • 07

    May

  • 18

    May

  • 29

    May

  • 18

    Apr

PINS Pinterest
$0.00

(0.00%)

04/15/19
DADA
04/15/19
INITIATION
DADA
Neutral
Pinterest initiated with a Neutral at DA Davidson
04/09/19
ATLE
04/09/19
INITIATION
Target $23
ATLE
Overweight
Atlantic bullish on Pinterest pre-IPO, calls valuation 'not challenging'
Atlantic Equities analyst James Cordwell earlier today initiated coverage of upcoming initial public offering Pinterest (PINS) with an Overweight rating and $23 price target. The company's 75M share IPO is expected to price between $15 and $17 per share. Pinterest's "unique and broadly appealing" proposition, which offers consumers the ability to view and collate visual recommendations, will enable "ongoing robust" user growth, Cordwell told investors in a research note. Further, the analyst expects "significant" monetization upside due to Pinterest's higher purchasing intent of the user base along with a lower current average revenue per user than other advertising-supported platform. Pinterest offers an attractive way to "diversify online advertising exposure" with non-GAAP profitability coming this year 2019 and a "not challenging" valuation, contends Cordwell.
04/09/19
ATLE
04/09/19
INITIATION
Target $23
ATLE
Overweight
Pinterest initiated with an Overweight at Atlantic Equities
Atlantic Equities analyst James Coredwell initiated Pinterest with an Overweight and $23 price target.
04/15/19
DADA
04/15/19
INITIATION
Target $16
DADA
Neutral
Pinterest initiated with a Neutral at DA Davidson
DA Davidson analyst Tom Forte initiated Pinterest with a Neutral rating and a price target of $16. The analyst says the company offers consumers an "impressive visual-based discovery platform for merchandise" and advertisers "a large and growing global base of consumers with purchase intent" - a combination that he believes will "translate into long-term sales and profitability growth." However, Forte also sees the valuation for Pinterest already reflecting his favorable view of the company's growth prospects. The analyst adds that the potential catalysts for Pinterest stock to trade higher in the next 12 months include "product improvements for advertisers, efforts to drive international usage and monetization, and expansion into new content verticals."
FIVE Five Below
$134.74

-0.22 (-0.16%)

04/11/19
04/11/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Five Below (FIVE) upgraded to Overweight from Neutral at JPMorgan with analyst Matthew Boss saying management expressed "strong confidence" in both the near-term and multi-year 20%-plus sales growth driving 20%-plus annual earnings growth. 2. CMS Energy (CMS) upgraded to Buy from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith saying shares are more attractive following recent underperformance and have been de-risked by the resolution of PURPA issues through the IRP settlement, removing the biggest overhang. 3. Cracker Barrel (CBRL) upgraded to Buy from Hold at Maxim. 4. Customers Bancorp (CUBI) upgraded to Buy from Neutral at B. Riley FBR with analyst Steve Moss saying with the T-Mobile launch imminent, the he finds the risk/reward attractive with the stock trading at 84% of tangible book value. 5. Hawaiian Holdings (HA) upgraded to Outperform from Neutral at Macquarie with analyst Susan Donofrio saying she believes investor sentiment is beginning to shift as concerns over Southwest (LUV) dramatically changing the pricing structure abate and raised estimates to reflect stronger expected earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/19
JPMS
04/11/19
UPGRADE
Target $150
JPMS
Overweight
JPMorgan upgrades Five Below with comp drives in early innings
JPMorgan analyst Matthew Boss upgraded Five Below to Overweight from Neutral and raised his price target for the shares to $150 from $133 after hosting management at his firm's Retail Round-Up. Management expressed "strong confidence" in both the near-term and multi-year 20%-plus sales growth driving 20%-plus annual earnings growth, Boss tells investors in a research note. The analyst believes the core drivers of Five Below's positive 3.8% trailing five-year average comp remain in early innings.
04/11/19
JPMS
04/11/19
UPGRADE
Target $150
JPMS
Overweight
Five Below upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Matthew Boss upgraded Five Below to Overweight from Neutral and raised his price target for the shares to $150 from $133.
04/15/19
BOFA
04/15/19
INITIATION
Target $150
BOFA
Buy
Five Below initiated with a Buy at BofA/Merrill
BofA/Merrill analyst David Buckley initiated Five Below with a Buy and $150 price target saying new store growth and its strategy of reinvesting in its products to improve its offering will result in mid-single digit comp growth through 2021.
LEVI Levi Strauss
$22.79

0.33 (1.47%)

04/15/19
SBSH
04/15/19
INITIATION
Target $27
SBSH
Buy
Levi Strauss initiated with a Buy at Citi
Citi analyst Paul Lejuez started Levi Strauss with a Buy rating and $27 price target. The company's "strong" momentum in recent years positions it well to further capitalize on growth opportunities as it develops its women's category, tops business and China businesses, Lejuez tells investors in a research note. He sees these as key drivers to help Levi generate high single to low double digit earnings growth in the coming years.
04/15/19
TLSY
04/15/19
INITIATION
Target $28
TLSY
Outperform
Levi Strauss initiated with an Outperform at Telsey Advisory
Telsey Advisory initiated Levi Strauss with an Outperform and $28 price target.
04/15/19
JPMS
04/15/19
INITIATION
Target $26
JPMS
Overweight
Levi Strauss initiated with an Overweight at JPMorgan
JPMorgan analyst Matthew Boss started Levi Strauss with an Overweight rating and $26 price target. The analyst views the combination of a "strong tenured management team" and brand heritage as a competitive advantage for Levi Strauss in expanding to a global lifestyle brand.
04/15/19
MSCO
04/15/19
INITIATION
Target $23
MSCO
Equal Weight
Levi Strauss initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Kimberly Greenberger started Levi Strauss with an Equal Weight rating and $23 price target. Her view is that the company still has "compelling" opportunities such as direct-to-consumer, international expansion and category diversification, but that while she is constructive on the stock "the market appears equally enthusiastic."
TOCA Tocagen
$9.91

-0.35 (-3.41%)

12/31/18
RILY
12/31/18
INITIATION
Target $22
RILY
Buy
Tocagen resumed with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico resumed coverage of Tocagen and kept his firm's Buy rating and $22 price target on the shares.
01/18/19
BARD
01/18/19
INITIATION
Target $20
BARD
Outperform
Tocagen initiated with an Outperform at Baird
Baird initiated Tocagen with an Outperform and $20 price target.
02/27/19
02/27/19
NO CHANGE

Tocagen reports Q4 EPS (96c), consensus (68c)
Reports Q4 revenue $9K, consensus $10K.
04/15/19
LEER
04/15/19
INITIATION
Target $11
LEER
Market Perform
Tocagen initiated with a Market Perform at SVB Leerink
SVB Leerink initiated Tocagen with a Market Perform and $11 price target.
ALC Alcon
$54.99

0.5 (0.92%)

04/11/19
SOCG
04/11/19
DOWNGRADE
SOCG
Sell
Societe Generale corrects error in work, downgrades Alcon to Sell
Societe Generale analyst Delphine Le Louet, who initiated Alcon yesterday with a Buy rating and CHF67 price target, said she identified an error in her model and has downgraded the stock to Sell from Buy after correcting her work. Her corrected discounted cash flow valuation analysis leads her to a new price target of CHF44, said the analyst, who apologized for the error and noted she made no changes to her P&L forecasts.
04/11/19
SOCG
04/11/19
DOWNGRADE
SOCG
Sell
Alcon downgraded to Sell from Buy at Societe Generale
04/10/19
SOCG
04/10/19
INITIATION
SOCG
Buy
Alcon initiated with a Buy at Societe Generale
04/15/19
JEFF
04/15/19
INITIATION
Target $70
JEFF
Buy
Alcon initiated with a Buy at Jefferies
Jefferies analyst Anthony Petrone started Alcon with a Buy rating and $70 price target. The analyst's consumer work points toward a $400M-$600M opportunity for Precision1 while his doctor survey points toward a $200M-$300M opportunity for PanOptix. He sees these and other drivers pushing Alcon's sales growth toward 6%.
AGN Allergan
$143.52

-1.42 (-0.98%)

04/11/19
EVER
04/11/19
INITIATION
Target $34
EVER
Outperform
Editas Medicine initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Editas Medicine (EDIT) with an Outperform rating and a price targets of $34. The analyst cites the company's "strong clinical positioning of lead program EDIT-101", saying that if its efficacy is demonstrated in LCA-10 and proven durable, it will likely have "significant uptake over Sepofarsen, which requires chronic dosing." Mehrotra adds that Editas Medicine's partnership with Allergan (AGN) "adds reinforcement".
04/02/19
STFL
04/02/19
NO CHANGE
Target $175
STFL
Hold
Stifel says abicipar improvement not enough to make Allergan drug competitive
After Allergan reported data from its 28-week open-label safety study, MAPLE, to evaluate the safety of abicipar produced via a modified manufacturing process, Stifel analyst Annabel Samimy noted that overall inflammation was reduced to 8.9% and severe inflammation to 1.6%. However, her talks with key opinion leading physicians lead her to conclude that the MAPLE inflammation rates are still too high compared to other "extremely safe" and effective options on the market today. Increasing competition on efficacy, dosing length, and price, as well as the still-high inflammation rates, continue to limit any meaningful commercial opportunity for abicipar, said Samimy, who keeps a Hold rating on Allergan shares.
03/22/19
ADAM
03/22/19
NO CHANGE
ADAM
Buy
Breast implant panel documents in-line with expectations, says Canaccord
Canaccord analyst Kyle Rose maintains his Buy rating on Sientra (SIEN) following the release of briefing documents ahead of next week's FDA panel meeting to review a range of topics related to the long-term benefits and risks of breast implants, stating that the documents appear to be in-line with expectations and do not appear to raise any materially new or concerning questions or data. However, given the warning letters sent this week to Sientra and J&J's (JNJ) Mentor unit, Rose said he expects the FDA to "take a strong tone" during the panel about the responsibility to support the collection and analysis of relevant safety and efficacy clinical data. Other makers of breast implants include Allergan (AGN) and Establishment Labs (ESTA).
04/15/19
JEFF
04/15/19
INITIATION
Target $155
JEFF
Hold
Allergan initiated with a Hold at Jefferies
Jefferies analyst David Steinberg started Allergan with a Hold rating and $155 price target. While the company has a dominant aesthetics business and a leading eyecare franchise, it is facing multiple pending competitors to Botox and $3.5B in loss of exclusivities for several key products, Steinberg tells investors in a research note. Further, following a string of pipeline setbacks, Allergan will be even more challenged to deliver its growth objectives over the coming years, says the analyst.

TODAY'S FREE FLY STORIES

ILMN

Illumina

$318.91

4.47 (1.42%)

17:36
04/25/19
04/25
17:36
04/25/19
17:36
Earnings
Illumina raises FY19 adj. EPS view to $6.63-$6.73 from $6.50-$6.60 »

Consensus $6.53. Backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 31

    May

  • 06

    Aug

  • 03

    Sep

HTH

Hilltop Holdings

$19.90

-0.19 (-0.95%)

17:35
04/25/19
04/25
17:35
04/25/19
17:35
Earnings
Hilltop Holdings reports Q1 EPS 41c, consensus 26c »

Hilltop's annualized…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

F

Ford

$9.41

-0.17 (-1.77%)

17:35
04/25/19
04/25
17:35
04/25/19
17:35
Hot Stocks
Ford backs long-term revenue growth target view exceeding global GDP »

Backs FY19 long-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

ILMN

Illumina

$318.91

4.47 (1.42%)

17:32
04/25/19
04/25
17:32
04/25/19
17:32
Earnings
Illumina reports Q1 adj. EPS $1.60, consensus $1.34 »

Reports Q1 revenue $846M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 31

    May

  • 06

    Aug

  • 03

    Sep

GIB

CGI Group

$71.16

0.36 (0.51%)

17:30
04/25/19
04/25
17:30
04/25/19
17:30
Downgrade
CGI Group rating change  »

CGI Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

ARGO

Argo Group

$74.21

-0.245 (-0.33%)

17:30
04/25/19
04/25
17:30
04/25/19
17:30
Upgrade
Argo Group rating change at William Blair »

Argo Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 11

    Jun

SBUX

Starbucks

$77.07

0.65 (0.85%)

, NSRGY

Nestle

$0.00

(0.00%)

17:30
04/25/19
04/25
17:30
04/25/19
17:30
Hot Stocks
Starbucks sees FY19 adjusted effective tax rate 19%-21% »

Says Nestle alliance…

SBUX

Starbucks

$77.07

0.65 (0.85%)

NSRGY

Nestle

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 07

    May

GCI

Gannett

$9.26

-0.11 (-1.17%)

17:29
04/25/19
04/25
17:29
04/25/19
17:29
Hot Stocks
Gannett still urges holders to vote 'FOR ALL' of its director nominees »

Gannett issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 16

    May

PRA

ProAssurance

$36.08

0.08 (0.22%)

17:28
04/25/19
04/25
17:28
04/25/19
17:28
Hot Stocks
ProAssurance concerned over loss trends in healthcare professional liability »

"Our concern about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 22

    May

  • 22

    May

NCR

NCR Corp.

$28.62

-0.755 (-2.57%)

17:27
04/25/19
04/25
17:27
04/25/19
17:27
Syndicate
NCR Corp. files to sell 20.39M shares of common stock »

Also files to sell up to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

PRA

ProAssurance

$36.08

0.08 (0.22%)

17:24
04/25/19
04/25
17:24
04/25/19
17:24
Earnings
ProAssurance reports Q1 EPS 8c, consensus 35c »

Reports Q1 revenue $269M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 22

    May

  • 22

    May

MRK

Merck

$76.33

1.6 (2.14%)

17:22
04/25/19
04/25
17:22
04/25/19
17:22
Hot Stocks
Merck provides update on Phase 3 KEYNOTE-062 trial »

Merck announced topline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 03

    May

  • 04

    May

  • 06

    May

  • 18

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 16

    Jul

  • 06

    Aug

  • 20

    Sep

ACB

Aurora Cannabis

$9.07

-0.045 (-0.49%)

, CGC

Canopy Growth

$48.20

-0.13 (-0.27%)

17:22
04/25/19
04/25
17:22
04/25/19
17:22
Initiation
Aurora Cannabis, Canopy Growth, HEXO Corp, Constellation Brands, AB InBev, Altria Group, Walgreens Boots Alliance, CVS Health, Rite Aid initiated  »

Desjardins initiates HEXO…

ACB

Aurora Cannabis

$9.07

-0.045 (-0.49%)

CGC

Canopy Growth

$48.20

-0.13 (-0.27%)

HEXO

HEXO Corp

$7.14

0.01 (0.14%)

STZ

Constellation Brands

$212.19

2.12 (1.01%)

BUD

AB InBev

$86.63

-1.57 (-1.78%)

MO

Altria Group

$51.42

-3.28 (-6.00%)

WBA

Walgreens Boots Alliance

$52.67

-0.8 (-1.50%)

CVS

CVS Health

$53.24

0.31 (0.59%)

RAD

Rite Aid

$8.98

-0.64 (-6.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 07

    May

  • 16

    May

  • 16

    May

  • 19

    May

  • 18

    Jun

DRQ

Dril-Quip

$43.59

-0.87 (-1.96%)

17:21
04/25/19
04/25
17:21
04/25/19
17:21
Earnings
Dril-Quip sees Q2 revenue at high end of $90M-$100M, consensus $95M »

Raises Q2 expectations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

SBUX

Starbucks

$77.07

0.65 (0.85%)

17:20
04/25/19
04/25
17:20
04/25/19
17:20
Hot Stocks
Starbucks says on track to deliver on capital return commitment »

Says on track to deliver…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

DRQ

Dril-Quip

$43.59

-0.87 (-1.96%)

17:20
04/25/19
04/25
17:20
04/25/19
17:20
Earnings
Dril-Quip reports Q1 EPS (17c), consensus (6c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

SBUX

Starbucks

$77.07

0.65 (0.85%)

17:17
04/25/19
04/25
17:17
04/25/19
17:17
Hot Stocks
Starbucks says 'well-positioned' for long-term growth in China »

Sees 6,000 China stores…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SBUX

Starbucks

$77.07

0.65 (0.85%)

17:13
04/25/19
04/25
17:13
04/25/19
17:13
Hot Stocks
Starbucks says will have Nitro Cold Brew in all U.S. stores by end of FY19 »

Says EMEA region nearly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LMT

Lockheed Martin

$328.97

-1.15 (-0.35%)

17:13
04/25/19
04/25
17:13
04/25/19
17:13
Hot Stocks
Lockheed Martin awarded $723.55M Army contract modification »

Lockheed Martinhas been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    Apr

  • 29

    May

  • 05

    Jun

MET

MetLife

$44.69

-0.22 (-0.49%)

, BLK

BlackRock

$474.56

-5.61 (-1.17%)

17:12
04/25/19
04/25
17:12
04/25/19
17:12
Hot Stocks
MetLife appoints Matthew Mosca as Global Head of Institutional Client Group »

MetLife Investment…

MET

MetLife

$44.69

-0.22 (-0.49%)

BLK

BlackRock

$474.56

-5.61 (-1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 02

    May

  • 23

    May

  • 03

    Jun

  • 11

    Jun

  • 18

    Jun

  • 18

    Jun

  • 27

    Oct

HEXO

HEXO Corp

$7.14

0.01 (0.14%)

17:10
04/25/19
04/25
17:10
04/25/19
17:10
Initiation
HEXO Corp initiated  »

HEXO Corp initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEM

Agnico Eagle

$40.67

0.09 (0.22%)

17:10
04/25/19
04/25
17:10
04/25/19
17:10
Hot Stocks
Agnico Eagle Q1 payable gold production of 398,217 oz versus 389,278 oz in 1Q18 »

In the first quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CGC

Canopy Growth

$48.20

-0.13 (-0.27%)

17:10
04/25/19
04/25
17:10
04/25/19
17:10
Initiation
Canopy Growth initiated  »

Canopy Growth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACB

Aurora Cannabis

$9.07

-0.045 (-0.49%)

17:09
04/25/19
04/25
17:09
04/25/19
17:09
Initiation
Aurora Cannabis initiated  »

Aurora Cannabis initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$57.59

-1.13 (-1.92%)

17:08
04/25/19
04/25
17:08
04/25/19
17:08
Hot Stocks
Intel down 7.7% to $53.20 after lowering FY outlook »

The company's Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 16

    May

  • 03

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.